Position in NVS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$216,743
+$3,657 QoQ
Shares Held
1,383
-0.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,284
of 1,603 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FIDELIS CAPITAL PARTNERS, LLC holds $51,570,809 across 10 Drug Manufacturers - General names. NVS ranks #10 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
55,734 | $14,154,763 | |
| 2 | LLY |
ELI LILLY & Co
|
11,461 | $13,746,668 | |
| 3 | ABBV |
AbbVie Inc.
|
38,686 | $9,734,945 | |
| 4 | MRK |
Merck & Co., Inc.
|
51,693 | $6,642,550 | |
| 5 | AMGN |
Amgen Inc
|
8,119 | $2,940,052 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
27,994 | $1,613,014 | |
| 7 | PFE |
Pfizer Inc
|
51,883 | $1,249,342 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
6,859 | $866,566 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $216,743 | 1,383 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $213,086 | 1,395 | Shares | Sole | 2026-05-06 | |
| No filing history on record for this holder in this stock. | ||||||